DOCSLIB.ORG

4. WNK Kinases in Invasion and Metastasis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
4. WNK Kinases in Invasion and Metastasis Emerging Signaling Pathways in Tumor Biology 2010 Editor Pedro A. Lazo IBMCC-Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain Transworld Research Network, T.C. 37/661 (2), Fort P.O. Trivandrum-695 023 Kerala, India Published by Transworld Research Network 2010; Rights Reserved Transworld Research Network T.C. 37/661(2), Fort P.O., Trivandrum-695 023, Kerala, India Editor Pedro A. Lazo Managing Editor S.G. Pandalai Publication Manager A. Gayathri Transworld Research Network and the Editor assume no responsibility for the opinions and statements advanced by contributors ISBN: 978-81-7895-477-6 Preface The specificity of biological effects in different cells types is determined by the composition of their proteome, the physical and functional interaction between different signaling pathways and theirs spatial and temporal organization in signaling complexes. Although the implication of some specific pathways with major phenotypes, such as proliferation, apoptosis or differentiation is well known, the final effect varies depending on cell type, which might even be the opposite. These phenotypes play an essential role, and are frequently deregulated in tumor cells, which make some of them potential targets for development of new drugs. In this context, protein kinases represent the main regulatory family, which can be activated and deactivated by reversible phosphorylation, or by integration in spatially organized signaling complexes with scaffold proteins. The human kinome is composed of 518 kinases and for many of them their characterization from the point of view of regulation and substrate specificity, as well as their integration in novel signaling pathways, or their effect on other better know pathways such as MAPK, are not yet understood. In this book we have focused the attention on some of the less well known kinases such as Cot1/Tpl2, LKB1, WNK, GSK3, VRK, and PLK3. Also there is a chapter on development of specific inhibitors for mitotic kinases. There are two additional chapters. One focused on the KSR scaffold protein, an organizer of signaling complexes and intracellular signal compartmentalization, as well as another on DUSP phosphatases, the key deactivator of regulated kinases, which comparatively receive little attention, but are an essential component in regulatory mechanisms. Pedro A. Lazo Contents Chapter 1 Modulation of Ras signaling by the KSR family of molecular scaffolds 1 Luís G. Pérez-Rivas, Stephanie Prieto and José Lozano Chapter 2 The biological function of the proto-oncogene Cot/tpl-2 (MAP kinase kinase kinase 8) 25 Margarita Fernández, Irene Soria, Marta López-Peláez Antonio Martín-Duce and Susana Alemany Chapter 3 WNK kinase signalling in cancer biology 43 Sónia Moniz and Peter Jordan Chapter 4 The tumour suppressor role of LKB1 in human cancer 71 Paola A. Marignani and Montse Sanchez-Cespedes Chapter 5 The role of glycogen synthase kinase-3 in the decision between cell survival and cell death 95 Roberta Venè and Francesca Tosetti Chapter 6 Polo-like kinase 3 in normal and tumor biology 117 Dazhong Xu and Wei Dai Chapter 7 Vaccinia-related kinase (VRK) signaling in cell and tumor biology 135 Marta Sanz-García, Alberto Valbuena, Inmaculada López-Sánchez Sandra Blanco, Isabel F. Fernández, Marta Vázquez-Cedeira and Pedro A. Lazo Chapter 8 Targeting mitotic kinases for anti-cancer treatment 157 Hae-ock Lee, Yoo-Kyung Lee, and Hyunsook Lee Chapter 9 Atypical DUSPs: 19 phosphatases in search of a role 185 Yolanda Bayón and Andrés Alonso Transworld Research Network 37/661 (2), Fort P.O. Trivandrum-695 023 Kerala, India Emerging Signaling Pathways in Tumor Biology, 2010: 1-23 ISBN: 978-81-7895-477-6 Editor: Pedro A. Lazo 1. Modulation of Ras signaling by the KSR family of molecular scaffolds Luís G. Pérez-Rivas, Stephanie Prieto and José Lozano Dpto. Biología Molecular y Bioquímica, Universidad de Málaga, 29071 Málaga, Spain Abstract. KSR proteins were initially identified in C. elegans and D. melanogaster as positive regulators of Ras signaling. Murine and human homologs were subsequently isolated, allowing for their characterization at the molecular level. The mammalian homologs are functionally classified as pseudokinases due to the lack of a catalytic lysine involved in the phosphotransfer reaction and found in most active kinases. Over the past 10 years, work done in several groups has allowed a detailed molecular characterization of KSR proteins, mainly at the functional level. In the near future, a more complete picture of the mode of action of KSR proteins will require additional studies at the structural level. However, the wealth of data currently known about KSR clearly indicates that it is a critical player in Ras signal transduction, functioning as a molecular scaffold that complexes the individual components of the Raf/MEK/ERK cascade into multiprotein signaling platforms (signalosomes). Here, we will review some of the well-established concepts regarding the regulation of Ras signaling by KSR proteins, in both normal and malignant cells. We will also include some recent and provocative data that sheds new light on the mechanism of KSR function. Correspondence/Reprint request: Dr. José Lozano, Dpto. Biología Molecular y Bioquímica, Universidad de Málaga. Campus de Teatinos s/n. 29071 Málaga, Spain. Phone: (+34) 95 213 6661, E-mail: [email protected] 2 Luís G. Pérez-Rivas et al. 1. Introduction The kinase suppressor of Ras (KSR) family of proteins comprise an evolutionary conserved group of molecular scaffolds that function as modulators of Ras signaling by bringing together the different components of the Raf/MEK/ERK cascade [1, 2]. KSR1, the founding member of the KSR family of proteins, was identified in 1995 by means of genetic screens in D. melanogaster and C. elegans [3-5]. At that time, a murine ksr1 gene was also cloned by Therrien et al. [5]. The corresponding mKSR1 protein has been, since then, the most studied member of the KSR family and currently serves as a model to explain the biological function of these proteins. To date, the family includes one gene in Drosophila (ksr), two genes in mammalian cells (KSR1 and KSR2) and two genes in C. elegans (ksr-1 and ksr-2) [4-8]. All KSR proteins identified so far have a C-terminal sequence which includes the 11 highly conserved subdomains found in most eukaryotic kinases and, therefore, they were initially named as if they were true kinases. However, the failure to find a KSR-specific direct substrate and, more importantly, the lack of an invariant catalytic residue (K) in subdomain II of mammalian KSR isoforms has led to the classification of these proteins in the pseudokinase subgroup of the human kinome, together with other proteins also containing degenerated kinase domains [9]. Currently, KSR is considered to function mainly as a molecular scaffold that facilitates the assembling of the individual components of the Raf/MEK/ERK signaling cascade [10-13]. Mammalian KSR proteins are expressed in most adult tissues, although their levels are usually very low and, frecuently hard to detect by immunoblotting [10, 14, 15]. The highest expression level has been reported for a brain-specific isoform (B-KSR1) [16]. Titration experiments, showed that, in fact, the in vivo KSR levels need to be carefully regulated and kept below a certain limit in order for KSR to properly function as a molecular scaffold [17]. This also applies to other known scaffolds, such as JNK-interacting protein 1 (JIP1) [18] and the molecular explanation for these requirement is summarized in Figure 1. Essentially, the concentration of a scaffold protein cannot be increased above its optimal level (defined by the stoichiometry of the reaction) to avoid chelation of its ligands into non- competent complexes [1]. For this reason, some of the early works aimed to define the role of KSR1 in Ras signaling resulted in contradictory outcomes, with some investigators reporting a negative role in ERK activation and Ras transformation and others reporting just the opposite [17, 19-24]. KSR1 function was mainly investigated by overexpressing mKSR1 in cultured cells and, therefore, the amount of ectopic mKSR1 was usually way above the endogenous (suboptimal) level, resulting in inhibition of Ras signaling. KSR proteins in Ras signaling 3 Under circumstances of low transfection efficiency, the ectopically expressed mKSR1 helped to reach the optimal scaffold concentration, enhancing signal transduction. To avoid this problem, which is inherent to the plasmid transfection methods, Morrison and coworkers developed an assay to measure the Ras-dependent ERK scaffolding activity of KSR in Xenopus laevis oocytes. The system allows for a careful titration of the amount of KSR expressed in each oocyte an scores their meiotic maturation (germinal vesicle breakdown, or GVBD) as the biological readout [1, 17]. More recently, the availability of immortalized KSR1-deficient cells has greatly facilitated the study of KSR function since variable amounts of mKSR1 proteins (wild-type or mutant) can be reintroduced in these cells by retroviral infection and subsequent sorting of cell populations with different KSR1 expression levels [25-27]. The following sections are a summary of the current molecular knowledge regarding KSR structure and function. Figure 1. The effective concentration of KSR1 is critical for an optimal scaffolding activity. This is achieved when the scaffold (KSR1, in red) and its ligands (C-Raf, MEK and ERK, in yellow, green and orange, respectively) are in a concentration near the stoichiometry of the reaction (B). Below such levels, a local increase in the effective concentration of KSR1 results in an increased signaling (A). However, an excess of the scaffold (i.e., a concentration higher than the optimal) results in the formation of non-productive complexes that block signaling (C). 4 Luís G. Pérez-Rivas et al. 2. Domain organization and function KSR proteins are similar to members of the Raf family of S/T kinases [4- 7], and as such are included in the tyrosine-like kinase (TLK) group of kinases [9].
Load more

Recommended publications
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB
    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
    [Show full text]
  • Table 2. Functional Classification of Genes Differentially Regulated After HOXB4 Inactivation in HSC/Hpcs
    Table 2. Functional classification of genes differentially regulated after HOXB4 inactivation in HSC/HPCs Symbol Gene description Fold-change (mean ± SD) Signal transduction Adam8 A disintegrin and metalloprotease domain 8 1.91 ± 0.51 Arl4 ADP-ribosylation factor-like 4 - 1.80 ± 0.40 Dusp6 Dual specificity phosphatase 6 (Mkp3) - 2.30 ± 0.46 Ksr1 Kinase suppressor of ras 1 1.92 ± 0.42 Lyst Lysosomal trafficking regulator 1.89 ± 0.34 Mapk1ip1 Mitogen activated protein kinase 1 interacting protein 1 1.84 ± 0.22 Narf* Nuclear prelamin A recognition factor 2.12 ± 0.04 Plekha2 Pleckstrin homology domain-containing. family A. (phosphoinosite 2.15 ± 0.22 binding specific) member 2 Ptp4a2 Protein tyrosine phosphatase 4a2 - 2.04 ± 0.94 Rasa2* RAS p21 activator protein 2 - 2.80 ± 0.13 Rassf4 RAS association (RalGDS/AF-6) domain family 4 3.44 ± 2.56 Rgs18 Regulator of G-protein signaling - 1.93 ± 0.57 Rrad Ras-related associated with diabetes 1.81 ± 0.73 Sh3kbp1 SH3 domain kinase bindings protein 1 - 2.19 ± 0.53 Senp2 SUMO/sentrin specific protease 2 - 1.97 ± 0.49 Socs2 Suppressor of cytokine signaling 2 - 2.82 ± 0.85 Socs5 Suppressor of cytokine signaling 5 2.13 ± 0.08 Socs6 Suppressor of cytokine signaling 6 - 2.18 ± 0.38 Spry1 Sprouty 1 - 2.69 ± 0.19 Sos1 Son of sevenless homolog 1 (Drosophila) 2.16 ± 0.71 Ywhag 3-monooxygenase/tryptophan 5- monooxygenase activation protein. - 2.37 ± 1.42 gamma polypeptide Zfyve21 Zinc finger. FYVE domain containing 21 1.93 ± 0.57 Ligands and receptors Bambi BMP and activin membrane-bound inhibitor - 2.94 ± 0.62
    [Show full text]
  • Intersectin 1 Forms Complexes with SGIP1 and Reps1 in Clathrin-Coated
    Biochemical and Biophysical Research Communications 402 (2010) 408–413 Contents lists available at ScienceDirect Biochemical and Biophysical Research Communications journal homepage: www.elsevier.com/locate/ybbrc Intersectin 1 forms complexes with SGIP1 and Reps1 in clathrin-coated pits ⇑ Oleksandr Dergai a, ,1, Olga Novokhatska a,1, Mykola Dergai a, Inessa Skrypkina a, Liudmyla Tsyba a, Jacques Moreau b, Alla Rynditch a a Department of Functional Genomics, Institute of Molecular Biology and Genetics, NASU, 150 Zabolotnogo Street, 03680 Kyiv, Ukraine b Molecular Mechanisms of Development, Jacques Monod Institute, Development and Neurobiology Program, UMR7592 CNRS – Paris Diderot University, 15 rue Hélène Brion, 75205 Paris Cedex 13, France article info abstract Article history: Intersectin 1 (ITSN1) is an evolutionarily conserved adaptor protein involved in clathrin-mediated endo- Received 7 October 2010 cytosis, cellular signaling and cytoskeleton rearrangement. ITSN1 gene is located on human chromosome Available online 12 October 2010 21 in Down syndrome critical region. Several studies confirmed role of ITSN1 in Down syndrome pheno- type. Here we report the identification of novel interconnections in the interaction network of this endo- Keywords: cytic adaptor. We show that the membrane-deforming protein SGIP1 (Src homology 3-domain growth Endocytosis factor receptor-bound 2-like (endophilin) interacting protein 1) and the signaling adaptor Reps1 (RalBP Adaptor proteins associated Eps15-homology domain protein) interact with ITSN1 in vivo. Both interactions are mediated Intersectin 1 by the SH3 domains of ITSN1 and proline-rich motifs of protein partners. Moreover complexes compris- Protein interactions SGIP1 ing SGIP1, Reps1 and ITSN1 have been identified. We also identified new interactions between SGIP1, Reps1 Reps1 and the BAR (Bin/amphiphysin/Rvs) domain-containing protein amphiphysin 1.
    [Show full text]
  • Download (Pdf)
    Invivoscribe's wholly-owned Laboratories for Personalized Molecular LabPMM LLC Medicine® (LabPMM) is a network of international reference laboratories that provide the medical and pharmaceutical communities with worldwide Located in San Diego, California, USA, it holds access to harmonized and standardized clinical testing services. We view the following accreditations and certifications: internationally reproducible and concordant testing as a requirement for ISO 15189, CAP, and CLIA, and is licensed to provide diagnostic consistent stratification of patients for enrollment in clinical trials, and the laboratory services in the states of California, Florida, foundation for establishing optimized treatment schedules linked to patient’s Maryland, New York, Pennsylvania, and Rhode Island. individual profile. LabPMM provides reliable patient stratification at diagnosis LabPMM GmbH and monitoring, throughout the entire course of treatment in support of Personalized Molecular Medicine® and Personalized Based in Martinsried (Munich), Germany. It is an ISO 15189 Molecular Diagnostics®. accredited international reference laboratory. CLIA/CAP accreditation is planned. Invivoscribe currently operates four clinical laboratories to serve partners in the USA (San Diego, CA), Europe (Munich, Germany), and Asia (Tokyo, Japan and Shanghai, China). These laboratories use the same critical LabPMM 合同会社 reagents and software which are developed consistently with ISO Located in Kawasaki (Tokyo), Japan and a licensed clinical lab. 13485 design control. Our cGMP reagents, rigorous standards for assay development & validation, and testing performed consistently under ISO 15189 requirements help ensure LabPMM generates standardized and concordant test results worldwide. Invivoscribe Diagnostic Technologies (Shanghai) Co., Ltd. LabPMM is an international network of PersonalMed Laboratories® focused on molecular oncology biomarker studies. Located in Shangai, China.
    [Show full text]
  • Supplemental Figure 1. Vimentin
    Double mutant specific genes Transcript gene_assignment Gene Symbol RefSeq FDR Fold- FDR Fold- FDR Fold- ID (single vs. Change (double Change (double Change wt) (single vs. wt) (double vs. single) (double vs. wt) vs. wt) vs. single) 10485013 BC085239 // 1110051M20Rik // RIKEN cDNA 1110051M20 gene // 2 E1 // 228356 /// NM 1110051M20Ri BC085239 0.164013 -1.38517 0.0345128 -2.24228 0.154535 -1.61877 k 10358717 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 /// BC 1700025G04Rik NM_197990 0.142593 -1.37878 0.0212926 -3.13385 0.093068 -2.27291 10358713 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 1700025G04Rik NM_197990 0.0655213 -1.71563 0.0222468 -2.32498 0.166843 -1.35517 10481312 NM_027283 // 1700026L06Rik // RIKEN cDNA 1700026L06 gene // 2 A3 // 69987 /// EN 1700026L06Rik NM_027283 0.0503754 -1.46385 0.0140999 -2.19537 0.0825609 -1.49972 10351465 BC150846 // 1700084C01Rik // RIKEN cDNA 1700084C01 gene // 1 H3 // 78465 /// NM_ 1700084C01Rik BC150846 0.107391 -1.5916 0.0385418 -2.05801 0.295457 -1.29305 10569654 AK007416 // 1810010D01Rik // RIKEN cDNA 1810010D01 gene // 7 F5 // 381935 /// XR 1810010D01Rik AK007416 0.145576 1.69432 0.0476957 2.51662 0.288571 1.48533 10508883 NM_001083916 // 1810019J16Rik // RIKEN cDNA 1810019J16 gene // 4 D2.3 // 69073 / 1810019J16Rik NM_001083916 0.0533206 1.57139 0.0145433 2.56417 0.0836674 1.63179 10585282 ENSMUST00000050829 // 2010007H06Rik // RIKEN cDNA 2010007H06 gene // --- // 6984 2010007H06Rik ENSMUST00000050829 0.129914 -1.71998 0.0434862 -2.51672
    [Show full text]
  • Clustering of the Structures of Protein Kinase Activation Loops
    bioRxiv preprint doi: https://doi.org/10.1101/395723; this version posted August 19, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Clustering of the structures of protein kinase activation loops: A new nomenclature for active and inactive kinase structures Vivek Modi Roland L. Dunbrack, Jr.* Institute for Cancer Research Fox Chase Cancer Center Philadelphia PA 19111 *[email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/395723; this version posted August 19, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Abstract TarGeting protein kinases is an important strateGy for intervention in cancer. Inhibitors are directed at the conserved active conformation or a variety of inactive conformations. While attempts have been made to classify these conformations, a structurally rigorous cataloGue of states has not been achieved. The kinase activation loop is crucial for catalysis and beGins with the conserved DFGmotif (Asp-Phe-Gly). This motif is observed in two major classes of conformations, DFGin - an ensemble of active and inactive conformations where the Phe residue is in contact with the C-helix of the N-terminal lobe, and DFGout - an inactive form where Phe occupies the ATP site exposinG the C-helix pocket.
    [Show full text]
  • Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers
    Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers Jiancheng Hu,1,2 Edward C. Stites,1 Haiyang Yu,1 Elizabeth A. Germino,1 Hiruy S. Meharena,3,4 Philip J.S. Stork,6 Alexandr P. Kornev,3,4,5 Susan S. Taylor,3,4,5,* and Andrey S. Shaw1,2,* 1Department of Pathology and Immunology 2Howard Hughes Medical Institute Washington University School of Medicine, 660 South Euclid, Box 8118, St. Louis, MO 63110, USA 3Department of Chemistry/Biochemistry 4Department of Pharmacology 5Howard Hughes Medical Institute University of California San Diego, 9500 Gilman Drive, Mail code 0654, La Jolla, CA 92093, USA 6Vollum Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA *Correspondence: [email protected] (S.S.T.), [email protected] (A.S.S.) http://dx.doi.org/10.1016/j.cell.2013.07.046 SUMMARY There are three isoforms of RAF: A-RAF, B-RAF, and C-RAF. Each appears to have a distinct mechanism of activation (Baljuls Although RAF kinases are critical for controlling et al., 2007; Galabova-Kovacs et al., 2006; Wimmer and Baccar- cell growth, their mechanism of activation is incom- ini, 2010). BRAF is considered to be more active and have a pletely understood. Recently, dimerization was simpler mechanism of activation in comparison to CRAF and shown to be important for activation. Here we show ARAF (Chong et al., 2001; Rebocho and Marais, 2013; Zhang that the dimer is functionally asymmetric with one and Guan, 2000). This difference can potentially explain why kinase functioning as an activator to stimulate activ- BRAF mutations are so common in cancer, in contrast to CRAF and ARAF, where mutations are rarely found (Davies ity of the partner, receiver kinase.
    [Show full text]
  • 9. Atypical Dusps: 19 Phosphatases in Search of a Role
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Digital.CSIC Transworld Research Network 37/661 (2), Fort P.O. Trivandrum-695 023 Kerala, India Emerging Signaling Pathways in Tumor Biology, 2010: 185-208 ISBN: 978-81-7895-477-6 Editor: Pedro A. Lazo 9. Atypical DUSPs: 19 phosphatases in search of a role Yolanda Bayón and Andrés Alonso Instituto de Biología y Genética Molecular, CSIC-Universidad de Valladolid c/ Sanz y Forés s/n, 47003 Valladolid, Spain Abstract. Atypical Dual Specificity Phosphatases (A-DUSPs) are a group of 19 phosphatases poorly characterized. They are included among the Class I Cys-based PTPs and contain the active site motif HCXXGXXR conserved in the Class I PTPs. These enzymes present a phosphatase domain similar to MKPs, but lack any substrate targeting domain similar to the CH2 present in this group. Although most of these phosphatases have no more than 250 amino acids, their size ranges from the 150 residues of the smallest A-DUSP, VHZ/DUSP23, to the 1158 residues of the putative PTP DUSP27. The substrates of this family include MAPK, but, in general terms, it does not look that MAPK are the general substrates for the whole group. In fact, other substrates have been described for some of these phosphatases, like the 5’CAP structure of mRNA, glycogen, or STATs and still the substrates of many A-DUSPs have not been identified. In addition to the PTP domain, most of these enzymes present no additional recognizable domains in their sequence, with the exception of CBM-20 in laforin, GTase in HCE1 and a Zn binding domain in DUSP12.
    [Show full text]
  • KSR1- and ERK-Dependent Translational Regulation of 2 the Epithelial-To-Mesenchymal Transition
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427224; this version posted January 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 KSR1- and ERK-dependent Translational Regulation of 2 the Epithelial-to-Mesenchymal Transition 3 Chaitra Rao1, Danielle E. Frodyma1, Siddesh Southekal2, Robert A. Svoboda3, Adrian R. Black1, 4 Chittibabu Guda2, Tomohiro Mizutani5, Hans Clevers5, Keith R. Johnson1,4, Kurt W. Fisher3, and 5 Robert E. Lewis1* 6 1 Eppley Institute, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA. 7 2 Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, University of 8 Nebraska Medical Center, Omaha, NE 68198, USA. 9 3 Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA. 10 4 Department of Oral Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA 11 5 Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, 3584CT Utrecht, The 12 Netherlands 13 *Correspondence: [email protected] 14 Abstract: 15 The epithelial-to-mesenchymal transition (EMT) is considered a transcriptional process 16 that induces a switch in cells from a polarized state to a migratory phenotype. Here we show that 17 KSR1 and ERK promote EMT through the preferential translation of Epithelial-Stromal 18 Interaction 1 (EPSTI1), which is required to induce the switch from E- to N-cadherin and 19 coordinate migratory and invasive behavior.
    [Show full text]
  • Profiling Data
    Compound Name DiscoveRx Gene Symbol Entrez Gene Percent Compound Symbol Control Concentration (nM) BSJ-03-123 AAK1 AAK1 94 1000 BSJ-03-123 ABL1(E255K)-phosphorylated ABL1 79 1000 BSJ-03-123 ABL1(F317I)-nonphosphorylated ABL1 89 1000 BSJ-03-123 ABL1(F317I)-phosphorylated ABL1 98 1000 BSJ-03-123 ABL1(F317L)-nonphosphorylated ABL1 86 1000 BSJ-03-123 ABL1(F317L)-phosphorylated ABL1 89 1000 BSJ-03-123 ABL1(H396P)-nonphosphorylated ABL1 76 1000 BSJ-03-123 ABL1(H396P)-phosphorylated ABL1 90 1000 BSJ-03-123 ABL1(M351T)-phosphorylated ABL1 100 1000 BSJ-03-123 ABL1(Q252H)-nonphosphorylated ABL1 56 1000 BSJ-03-123 ABL1(Q252H)-phosphorylated ABL1 97 1000 BSJ-03-123 ABL1(T315I)-nonphosphorylated ABL1 100 1000 BSJ-03-123 ABL1(T315I)-phosphorylated ABL1 85 1000 BSJ-03-123 ABL1(Y253F)-phosphorylated ABL1 100 1000 BSJ-03-123 ABL1-nonphosphorylated ABL1 60 1000 BSJ-03-123 ABL1-phosphorylated ABL1 79 1000 BSJ-03-123 ABL2 ABL2 89 1000 BSJ-03-123 ACVR1 ACVR1 100 1000 BSJ-03-123 ACVR1B ACVR1B 95 1000 BSJ-03-123 ACVR2A ACVR2A 100 1000 BSJ-03-123 ACVR2B ACVR2B 96 1000 BSJ-03-123 ACVRL1 ACVRL1 84 1000 BSJ-03-123 ADCK3 CABC1 90 1000 BSJ-03-123 ADCK4 ADCK4 91 1000 BSJ-03-123 AKT1 AKT1 100 1000 BSJ-03-123 AKT2 AKT2 98 1000 BSJ-03-123 AKT3 AKT3 100 1000 BSJ-03-123 ALK ALK 100 1000 BSJ-03-123 ALK(C1156Y) ALK 78 1000 BSJ-03-123 ALK(L1196M) ALK 100 1000 BSJ-03-123 AMPK-alpha1 PRKAA1 93 1000 BSJ-03-123 AMPK-alpha2 PRKAA2 100 1000 BSJ-03-123 ANKK1 ANKK1 89 1000 BSJ-03-123 ARK5 NUAK1 98 1000 BSJ-03-123 ASK1 MAP3K5 100 1000 BSJ-03-123 ASK2 MAP3K6 92 1000 BSJ-03-123 AURKA
    [Show full text]
  • Src-Family Kinases Impact Prognosis and Targeted Therapy in Flt3-ITD+ Acute Myeloid Leukemia
    Src-Family Kinases Impact Prognosis and Targeted Therapy in Flt3-ITD+ Acute Myeloid Leukemia Title Page by Ravi K. Patel Bachelor of Science, University of Minnesota, 2013 Submitted to the Graduate Faculty of School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2019 Commi ttee Membership Pa UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE Commi ttee Membership Page This dissertation was presented by Ravi K. Patel It was defended on May 31, 2019 and approved by Qiming (Jane) Wang, Associate Professor Pharmacology and Chemical Biology Vaughn S. Cooper, Professor of Microbiology and Molecular Genetics Adrian Lee, Professor of Pharmacology and Chemical Biology Laura Stabile, Research Associate Professor of Pharmacology and Chemical Biology Thomas E. Smithgall, Dissertation Director, Professor and Chair of Microbiology and Molecular Genetics ii Copyright © by Ravi K. Patel 2019 iii Abstract Src-Family Kinases Play an Important Role in Flt3-ITD Acute Myeloid Leukemia Prognosis and Drug Efficacy Ravi K. Patel, PhD University of Pittsburgh, 2019 Abstract Acute myelogenous leukemia (AML) is a disease characterized by undifferentiated bone-marrow progenitor cells dominating the bone marrow. Currently the five-year survival rate for AML patients is 27.4 percent. Meanwhile the standard of care for most AML patients has not changed for nearly 50 years. We now know that AML is a genetically heterogeneous disease and therefore it is unlikely that all AML patients will respond to therapy the same way. Upregulation of protein-tyrosine kinase signaling pathways is one common feature of some AML tumors, offering opportunities for targeted therapy.
    [Show full text]
  • The Regulatory Roles of Phosphatases in Cancer
    Oncogene (2014) 33, 939–953 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc REVIEW The regulatory roles of phosphatases in cancer J Stebbing1, LC Lit1, H Zhang, RS Darrington, O Melaiu, B Rudraraju and G Giamas The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3--kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies. Oncogene (2014) 33, 939–953; doi:10.1038/onc.2013.80; published online 18 March 2013 Keywords: cancer; phosphatases; solid tumours GASTROINTESTINAL MALIGNANCIES abs in sera were significantly associated with poor survival in Oesophageal cancer advanced ESCC, suggesting that they may have a clinical utility in Loss of PTEN (phosphatase and tensin homologue deleted on ESCC screening and diagnosis.5 chromosome 10) expression in oesophageal cancer is frequent, Cao et al.6 investigated the role of protein tyrosine phosphatase, among other gene alterations characterizing this disease. Zhou non-receptor type 12 (PTPN12) in ESCC and showed that PTPN12 et al.1 found that overexpression of PTEN suppresses growth and protein expression is higher in normal para-cancerous tissues than induces apoptosis in oesophageal cancer cell lines, through in 20 ESCC tissues.
    [Show full text]